Your browser doesn't support javascript.
loading
Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
Barrington, David A; Riedinger, Courtney; Haight, Paulina J; Tubbs, Crystal; Cohn, David E.
Affiliation
  • Barrington DA; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America. Electronic address: David.Barrington@osumc.edu.
  • Riedinger C; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
  • Haight PJ; Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
  • Tubbs C; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
  • Cohn DE; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Gynecol Oncol ; 165(3): 500-505, 2022 06.
Article in En | MEDLINE | ID: mdl-35422338
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Lung Neoplasms Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2022 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Lung Neoplasms Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2022 Document type: Article Country of publication: United States